The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's drug for patients with a rare and ...

US FDA approves Nuvation Bio’s taletrectinib for treatment of advanced ROS1-positive non-small cell lung cancer: New York Saturday, June 14, 2025, 14:00 Hrs [IST] Nuvation Bio I ...

The US Food and Drug Administration (FDA) has approved Nuvation Bio’s Ibtrozi (taletrectinib) to treat adults with a rare and ...

Nuvation Bio Inc., a global oncology company, received U.S. Food and Drug Administration (FDA) approval of Ibtrozi ...

Read the latest analysis on Nuvation Bio stock. Solid financials, positive analyst sentiment, and insider buying support ...

Nuvation Bio is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment ...

FDA approves Ibtrozi for ROS1+ non-small cell lung cancer based on data from over 300 patients in two pivotal trials showing ...

The US Food and Drug Administration (FDA) yesterday approved Nuvation Bio’s (NYSE: NUVB) Ibtrozi (taletrectinib), a kinase ...

Short interest in Nuvation Bio Inc (NYSE:NUVB) decreased during the last reporting period, falling from 32.10M to 30.81M. This put 12.73% of the company's publicly available shares short.

The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's therapy for patients with a type of ...